Last reviewed · How we verify
Chenodeoxycholic Acid
At a glance
| Generic name | Chenodeoxycholic Acid |
|---|---|
| Also known as | CDCA, chenodeoxycholate |
| Sponsor | US Department of Veterans Affairs |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones). (PHASE4)
- Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 (PHASE2)
- A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (PHASE2)
- Intravenous Infusion of CAP-1002 in Patients With COVID-19 (PHASE2)
- A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX) (PHASE3)
- Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) (PHASE3)
- Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition (PHASE4)
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chenodeoxycholic Acid CI brief — competitive landscape report
- Chenodeoxycholic Acid updates RSS · CI watch RSS
- US Department of Veterans Affairs portfolio CI